These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 15888422)

  • 21. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia.
    Keefe RS; Vinogradov S; Medalia A; Silverstein SM; Bell MD; Dickinson D; Ventura J; Marder SR; Stroup TS
    Schizophr Bull; 2011 Sep; 37(5):1057-65. PubMed ID: 20194249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior.
    Hogarty GE; Flesher S; Ulrich R; Carter M; Greenwald D; Pogue-Geile M; Kechavan M; Cooley S; DiBarry AL; Garrett A; Parepally H; Zoretich R
    Arch Gen Psychiatry; 2004 Sep; 61(9):866-76. PubMed ID: 15351765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of separable cognitive factors in schizophrenia.
    Nuechterlein KH; Barch DM; Gold JM; Goldberg TE; Green MF; Heaton RK
    Schizophr Res; 2004 Dec; 72(1):29-39. PubMed ID: 15531405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.
    Keefe RS; Mohs RC; Bilder RM; Harvey PD; Green MF; Meltzer HY; Gold JM; Sano M
    Schizophr Bull; 2003; 29(1):45-55. PubMed ID: 12908660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain.
    Rodriguez-Jimenez R; Bagney A; Garcia-Navarro C; Aparicio AI; Lopez-Anton R; Moreno-Ortega M; Jimenez-Arriero MA; Santos JL; Lobo A; Kern RS; Green MF; Nuechterlein KH; Palomo T
    Schizophr Res; 2012 Feb; 134(2-3):279-84. PubMed ID: 22192501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.
    Young JW; Powell SB; Risbrough V; Marston HM; Geyer MA
    Pharmacol Ther; 2009 May; 122(2):150-202. PubMed ID: 19269307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychometric comparison of computerized and standard administration of the neurocognitive assessment instruments selected by the CATIE and MATRICS consortia among patients with schizophrenia.
    O'Halloran JP; Kemp AS; Gooch KN; Harvey PD; Palmer BW; Reist C; Schneider LS
    Schizophr Res; 2008 Nov; 106(1):33-41. PubMed ID: 18160262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchers.
    Tcheremissine OV; Castro MA; Gardner DR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):7-14. PubMed ID: 22059602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiative.
    Marder SR; Fenton W; Youens K
    Am J Psychiatry; 2004 Jan; 161(1):25. PubMed ID: 14702244
    [No Abstract]   [Full Text] [Related]  

  • 32. [Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].
    Rodríguez-Jiménez R; Bagney A; Moreno-Ortega M; García-Navarro C; Aparicio AI; López-Antón R; de la Oliva J; Jiménez-Arriero MÁ; Santos JL; Lobo A; Palomo T
    Rev Neurol; 2012 Nov; 55(9):549-55. PubMed ID: 23111994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial.
    Stroup S; Appelbaum P; Swartz M; Patel M; Davis S; Jeste D; Kim S; Keefe R; Manschreck T; McEvoy J; Lieberman J
    Schizophr Res; 2005 Dec; 80(1):1-8. PubMed ID: 16182516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The MATRICS consensus cognitive battery: what we know 6 years later.
    Green MF; Harris JG; Nuechterlein KH
    Am J Psychiatry; 2014 Nov; 171(11):1151-4. PubMed ID: 25756630
    [No Abstract]   [Full Text] [Related]  

  • 35. Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial.
    Wykes T; Newton E; Landau S; Rice C; Thompson N; Frangou S
    Schizophr Res; 2007 Aug; 94(1-3):221-30. PubMed ID: 17524620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Brazilian standardization of the MATRICS consensus cognitive battery (MCCB): Psychometric study.
    Fonseca AO; Berberian AA; de Meneses-Gaya C; Gadelha A; Vicente MO; Nuechterlein KH; Bressan RA; Lacerda ALT
    Schizophr Res; 2017 Jul; 185():148-153. PubMed ID: 28110814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.
    Grant PM; Huh GA; Perivoliotis D; Stolar NM; Beck AT
    Arch Gen Psychiatry; 2012 Feb; 69(2):121-7. PubMed ID: 21969420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stimulating the development of drug treatments to improve cognition in schizophrenia.
    Green MF
    Annu Rev Clin Psychol; 2007; 3():159-80. PubMed ID: 17716052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.